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Abstract. In radiation therapy planning, uncertainties in the definition of the target vol-
ume yield a risk of underdosing the tumor. The traditional corrective action in the context
of external beam radiotherapy (EBRT) expands the clinical target volume (CTV) with
an isotropic margin to obtain the planning target volume (PTV). However, the EBRT-
based PTV concept is not directly applicable to brachytherapy (BT) since it can lead
to undesirable dose escalation. Here, we present a treatment plan optimization model
that uses worst-case robust optimization to account for delineation uncertainties in inter-
stitial high-dose-rate BT of the prostate. A scenario-based method was developed that
handles uncertainties in index sets. Heuristics were included to reduce the calculation
times to acceptable proportions. The approach was extended to account for delineation
uncertainties of an organ at risk (OAR) as well. The method was applied on data from
prostate cancer patients and evaluated in terms of commonly used dosimetric perfor-
mance criteria for the CTV and relevant OARs. The robust optimization approach was
compared against the classical PTV margin concept and against a scenario-based CTV
margin approach. The results show that the scenario-based margin and the robust opti-
mization method are capable of reducing the risk of underdosage to the tumor. As
expected, the scenario-based CTVmargin approach leads to dose escalationwithin the tar-
get, whereas this can be prevented with the robust model. For cases where rectum sparing
was a binding restriction, including uncertainties in rectum delineation in the planning
model led to a reduced risk of a rectum overdose, and in some cases, to reduced target
coverage.
History: Accepted by Allen Holder, Area Editor for Applications in Biology, Medicine, and Healthcare.
Supplemental Material: The online supplement is available at https://doi.org/10.1287/ĳoc.2018.0815.
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1. Introduction
Cancer can be treated by surgery, chemotherapy, radio-
therapy or a combination of thesemodalities. For deep-
seated solid tumors, radiotherapy is an adequate treat-
ment option as ionising radiation can penetrate healthy
tissues to reach the tumor. Radiation therapy can be
delivered by external beam radiotherapy (EBRT) or by
brachytherapy (BT). Radiation in EBRT comes from an
external source and is pointed at the tumor, while with
BT a small radioactive source is placed inside or close
to the tumor.
For prostate cancer, which is the most common type
of cancer among men in the Western world, interstitial
high-dose rate brachytherapy (HDR-BT) with a tem-
porary implant has been shown to be an adequate
treatment (Yamada et al. 2012). A template contain-
ing a large number of evenly spaced holes is typically
placed in front of the patient’s perineum while he is
under anesthesia in dorsal position. Depending on the
dimensions of the prostate, around 15 to 20 of these
holes are selected for implanting a hollow catheter into
the prostate. After implantation of all needles, a remote
afterloader device successively advances a 192Ir source
through the needles. The source stops in each catheter
at predetermined locations (dwell positions) inside the
target volume for a predetermined amount of time
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(dwell time) to deposit a sufficiently high dose to the
tumor. The source is then removed from the patient
and stored in the afterloader device for future use.
Radiotherapy inevitably results in exposure of
healthy tissues surrounding the tumor. The spatial
distribution of catheters and dwell positions, together
with the dwell times, determine the shape and mag-
nitude of the dose distribution. The goal of treatment
planning is to determine the number and locations of
catheters together with the dwell times such that the
tumor receives a sufficiently high dose to sterilize the
tumorous cells while limiting dose exposure to sur-
rounding organs at risk (OARs) as much as possible
to minimize the risk of side effects. The problem of
designing a treatment plan for HDR-BT lends itself to
be formulated as amathematical optimization problem
(De Boeck et al. 2014).
A scan of the patient’s anatomy is made before treat-
ment planning, and the target volume and the OARs
are delineated (Figure 1). These delineations are sub-
ject to intra- and inter-observer variability, i.e., the same
observer does not draw identical contours for the same
individual case, and different observers produce differ-
ent delineations for an identical case, respectively (see
e.g., Villeirs et al. 2005 and De Brabandere et al. 2012).
This implies uncertainty in the location and shape of
the delineated structures, and thus uncertainty in the
volumes to be irradiated and those to be spared. To
numerically optimize and evaluate a dose distribution,
these structures are discretized into finite sets of small
volume elements that are considered dose calculation
points. The dose deposited in each calculation point is
the superposition of the dose rate contributions from
Figure 1. A Transrectal Ultrasound Image with Delineated
Target Volume (Black) Extended with an Isotropic Margin
(White), Rectum (Gray, Dashed), and Urethra (Gray, Solid)
Note. The white delineation is a safety margin accounting for uncer-
tainties, see Section 1.1.1.
Figure 2. Two Delineations of a Prostatic Target Volume
Based on a Transversal Ultrasound Imaging Scan
Note. Both delineations yield a different set of calculation points
residing in the structure: The gray points with a black outline reside
in both structures, the white and black points only in the white and
black delineation, respectively.
all the dwell positions weighted by their respective
dwell times. Hence, uncertainties in the delineations
translate into uncertainty as to whether a calculation
point belongs to a certain structure (Figure 2). This
implies that there is uncertainty in the index sets of
the optimization model. So far, to our knowledge, opti-
mization methods have not addressed this type of
uncertainty. Therefore, our aim here is to develop an
optimization method that is robust against uncertainty
in index sets, and that consequently can be applied
for robust optimization of HDR-BT dose distributions
incorporating delineation uncertainties.
1.1. Review of Methods Accounting for
Uncertainties in Treatment Planning from
Clinical Practice and Literature
The classical way to address geometrical uncertainties
in EBRT planning is to apply a margin around the
tumor volume such that a sufficiently large volume
receives the prescribed therapeutic dose (e.g., VanHerk
et al. 2002, Van Herk 2004). A more recent approach
uses computational methods to numerically account
for uncertainties during the treatment planning opti-
mization process.Methods such as stochastic program-
ming (e.g., Unkelbach and Ulfke 2004, Bohoslavsky
et al. 2013) and worst-case robust optimization (e.g.,
Chan et al. 2006, Bortfeld et al. 2008, Fredriksson 2013)
have been suggested for this task.
1.1.1. Margin Approach. According to international
consensus guidelines published in the ICRU 62 report
(International Commission on Radiation Units and
Measurements 1999), uncertainties in EBRT should be
accounted for by applying a margin around the tumor
volume. Treatment preparation starts by delineating
the gross palpable, visible or clinically demonstrable
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location of the tumor on a scan, yielding the gross
tumor volume (GTV). Because microscopic disease
spread surrounding the GTV is invisible on the scan,
the GTV is expanded with a certain margin, resulting
in the clinical target volume (CTV). An additional mar-
gin is applied to account for geometrical uncertainties
in treatment planning (e.g., errors due to organ filling
and movement) and delivery (e.g., set-up errors due
to patient and beam positioning), which results in the
planning target volume (PTV).
The PTV concept as described in the ICRU 62 report
has been developed for EBRT, where the aim is to ex-
pand the dose distribution into a homogeneous plateau
reaching beyond the CTV. However, for BT (Tanderup
et al. 2010, p. 499) noted that “a homogeneous dose can-
not be obtained in and around a brachytherapy CTV,”
since adding PTV margins would lead to an undesir-
able dose escalation within the target. Applying a mar-
gin around the CTV to account for delineation uncer-
tainties is thus not applicable for BT. Nevertheless, the
margin recipe is currently used in BT practice.
1.1.2. Robust Optimization. So far, robust optimiza-
tion and stochastic programming have only been ap-
plied to treatment planning models for EBRT. Stochas-
tic programming considers the probability distribution
of an uncertain parameter, for example through opti-
mizing the expectation of the objective function or by
restricting the probability of constraint violations (e.g.,
Chu et al. 2005, Olafsson and Wright 2006, Unkelbach
and Ulfke 2004, Bohoslavsky et al. 2013, Fredriksson
2013). This inherently requires knowledge or assump-
tions about the probability distribution of the uncer-
tain parameter. However, such information is typically
unavailable,which is the case in our application.Worst-
case robust optimization instead assumes an uncer-
tainty region or a scenario-set in which the uncertain
parameter resides. A worst-case robust optimization
model only considers solutions that are robust fea-
sible, i.e., solutions that are feasible for all possible
realizations of the parameters. Among these solutions,
a worst-case robust optimization problem selects the
solution that minimizes (maximizes) the maximum
(minimum) over all possible parameter values or sce-
narios of the objective function (Ben-Tal et al. 2009).
Worst-case robust optimization thus yields treatment
plans that perform better in the worst- case scenario
(Fredriksson 2012). Robust optimization for EBRT has
been considered by various groups and can be applied
to treatment planning models at three different lev-
els: One can require robustness per calculation point
(e.g., Chan et al. 2006, Bortfeld et al. 2008, Liu et al.
2012), per objective and constraint (Chen et al. 2011) or
for the complete model (e.g., Fredriksson et al. 2011).
For a detailed comparison of these three approaches
for proton therapy planning, see Fredriksson and
Bokrantz (2014). In our opinion, each constraint should
be satisfied in all of the scenarios, and the robustness
of each objective should be considered separately (as
opposed to an aggregate of the objectives). We have
a single objective and several planning constraints in
our model, and we apply robust optimization to each
objective and constraint.
The methods described above have been applied
to EBRT planning models for various types of uncer-
tainties (e.g., organ motion or set-up uncertainties),
but, to our knowledge, none have considered delin-
eation uncertainties. However, uncertainties in target
volume delineation are known to be among the major
causes of geometrical uncertainties (Weiss and Hess
2003) in EBRT and BT. The importance of accounting
for any type of uncertainty in BT planning models has
been emphasized by Kirisits et al. (2014). In particu-
lar, they note that intra- and inter-observer delineation
variabilities, together with intra- and inter-fraction set-
up uncertainties, contribute most to dosimetric uncer-
tainty. Also, Rylander et al. (2017) found that delin-
eation uncertainties can lead to a degradation of dose.
To our knowledge, methods for robust treatment plan-
ning have so far only considered uncertainties that
yield uncertainty in the location of the calculation point
relative to the radiation source (e.g., through organ
motion or set-up uncertainties), while the structure
to which the calculation point belongs is fixed. This
implies uncertainty in the dose rate (i.e., the dose per
unit time), which is an important input parameter in
treatment planning optimization models. On the other
hand, delineation uncertainties do not change the loca-
tion of a calculation point, so the dose rate remains
fixed. Instead, they yield uncertainty in the structure to
which a calculation point belongs. To our knowledge,
the literature on robust optimization only considers
uncertainty in input parameters. As our problem con-
cerns uncertainty in index sets, we cannot use previ-
ously developed models: a new approach is required.
1.2. Aim and Contribution of the Paper
Our goal here is to take delineation uncertainties into
account in the treatment planning optimization pro-
cess for prostate HDR-BT using a worst-case robust
optimization approach.Wedevelop aworst-case robust
optimization method to incorporate uncertainties in
index sets. We aim to reduce the risk of underdosing
the CTV while respecting the predefined OAR con-
straints.Wecompareourmethod to the classicalmargin
approach.
The contributions of this work are (1) using com-
putational methods to incorporate delineation uncer-
tainties in treatment plan optimization, (2) extending
the robust optimization approach to account for uncer-
tainties in index sets, (3) using robust optimization to
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address uncertainties in BT, and (4) providing a speed-
up for the nominal BT treatment planning model that
optimizes clinical objectives (Gorissen et al. 2013).
This paper is organized as follows. In Section 2,
HDR-BT plan optimization is further clarified (Sec-
tion 2.1) and the nominal model for HDR-BT of
prostate cancer is introduced (Section 2.2). In Sec-
tion 2.3 three methods to address delineation uncer-
tainties are discussed. An extension of the model to
account for rectum delineation uncertainties is pre-
sented in Section 2.4, and methods for reducing the
calculation times are presented in Section 2.5. The com-
putational experiments and their results, along with a
comparison of the three approaches, are presented in
Section 3. A discussion and conclusion are provided in
Sections 4 and 5, respectively.
2. Treatment Plan Optimization Model
2.1. Dose Prescription and Plan Evaluation
The dosimetric quality of a treatment plan is usu-
ally evaluated using dose-volume histograms (DVHs).
These metrics are denoted by Dx%(S) and Dxcc(S),
which reflect theminimumdose received by the hottest
x% and x cc of the structure volume S, respectively, or
by Vy%(S) and VyGy(S), which denotes the fraction of
the structure volume S receiving at least y% of the pre-
scribed tumor dose or y Gy. A treatment plan should
satisfy pre-set DVH constraints. An example of a dose
prescription protocol for prostate HDR-BT, for which
the rectum and urethra are the most relevant OARs,
is presented in Table 1. Here, D90%(PTV) is given as
a percentage of the prescribed tumor dose. Note that
uncertainties are accounted for using a CTV-to-PTV
margin and that dose prescriptions are defined for the
PTV and not for the CTV. The same prescriptions are
used for the PTV in clinical practice; we also use them
to assess plan quality.
2.2. Nominal Treatment Planning Model
The optimization models currently used by treatment
planning systems assign a penalty to each calculation
point based on the difference between the planned
and the prescribed dose, and they minimize the total
penalty (e.g., Lessard and Pouliot 2001). Because such
penalties are a surrogate for the actual planning goals,
which is to satisfy the pre-set DVH criteria, recently
Table 1. Dose-Volume Criteria Based on the Protocol by
Hoskin et al. (2007)
PTV (%) Rectum (Gy) Urethra (Gy)
D90% ≥ 100 D10% ≤ 7.2 D10% ≤ 10
V100% ≥ 95 D2cc ≤ 6.7 D0.1cc ≤ 10
V150% ≤ 55 Dmax ≤ 8 Dmax ≤ 10.6
V200% ≤ 20
developed methods directly optimize the DVH met-
rics (Siauw et al. 2011, Gorissen et al. 2013, Holm et al.
2013). We use the model from Gorissen et al. (2013).
Catheter locations and dwell time distributions are
optimized in Gorissen et al. (2013), where active dwell
locations are given for each candidate catheter loca-
tion with a 3 mm separation. The goal is to maximize
the fraction of the target volume receiving at least the
prescribed dose, denoted by V100%(CTV). The follow-
ing model is referred to as the linear dose-volume, or
(LDV):




s.t. ÛdTi t ≥ viDpres ∀ i ∈ IC (1)
ÛdTi t ≤ LR + (HR − LR)(1−wi), ∀ i ∈ IR
(2)∑
i∈IR
wi ≥ τR |IR | (3)
t ≥ 0
vi ∈ {0, 1} ∀ i ∈ IC
wi ∈ {0, 1} ∀ i ∈ IR
[see Section 1 in the online supplement
for additional constraints].
Here, Ûdi ∈ | J |+ is the vector with dose rates from each
dwell position to calculation point i; IC denotes the set
of dose calculation points in the CTV, and J denotes the
set of dwell positions. The optimization variable t ∈ | J |+
contains the (nonnegative) dwell times of all dwell
positions. As a result, ÛdTi t is the total dose planned to be
delivered to calculation point i. Dpres is the prescribed
dose to the PTV, and vi is an auxiliary variable that
equals 1 if calculation point i receives at least the pre-
scribed dose, and 0 otherwise. The objectivemaximizes
the fraction of calculation points receiving at least the
prescribed dose. Constraint (2) ensures that no calcu-
lation point in the rectum receives a dose above HR.
The variable wi equals 1 if calculation point i receives a
dose below LR, and 0 otherwise. Constraints (2) and (3)
together restrict the fraction of calculation points in the
rectum receiving a dose above LR to be at most τR.
Additional constraints are included to restrict the
dose to the urethra and to choose the number of
catheters and their locations (see Section 1 of the online
supplement). These constraints are not provided in
detail here, as they remain the same in the robustmodel.
2.3. Accounting for Delineation
Uncertainties of the PTV
We compare three approaches to incorporate delin-
eation uncertainties in the plan optimization. These
approaches are an isotropic CTV-to-PTV margin cur-
rently used in the clinic, a scenario-based CTV-to-PTV
margin, and a robust optimization approach.
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2.3.1. Isotropic CTV-to-PTV Margin. Despite the fact
that a CTV-to-PTV margin seems unsuitable for HDR
BT, such a tactic is currently used in the clinic to
account for delineation uncertainties. As we compare
our robust approach to the current clinical standard,
we consider the isotropic CTV-to-PTV margin that
replaces the set IC by IP in model (LDV), the latter of
which is the set of calculation points in the PTV. An
isotropicmargin of 2mm is used in (Hoskin et al. 2013).
2.3.2. Scenario-Based CTV-to-PTV Margin. Given a
nominal delineation of the CTV and using measure-
ments on delineation inaccuracies from Smith et al.
(2007), we generate scenarios for possible delineations
and the corresponding sets of CTV calculation points.
Because the CTV-to-PTV margin is smaller than the
delineation uncertainty reported in the literature, the
PTV does not fully contain all the CTV scenarios, and
IP does not contain all of the calculation points that are
in the CTV according to at least one scenario. There-
fore, we also test the use of a scenario-based margin.
The union of all CTV scenarios is considered as the
PTV. The set of all calculation points that may be in the
CTV according to our scenario set, denoted by I˜C , is
used instead of the set IC in (LDV).
2.3.3. Robust Optimization. We use a scenario-based
approach for our robust optimization model. We know
the set of calculation points within the CTV for each
scenario in the set S. This information is stored in
matrix C, a |S | × |I | matrix, where each row corre-
sponds to a scenario and each column corresponds to
a calculation point. The entry on the sth row in the
ith column equals 1 if calculation point i resides in
the CTV for scenario s, and 0 otherwise. This matrix
is used to calculate CTV coverage for each scenario s
as V s100%(CTV)  Csv/Cs e, where Cs denotes row s of
matrix C, e is the all-ones vector, and v is as before. The
numerator counts the number of calculation points that
receive at least the prescribed dose and are in the CTV
according to scenario s, while the denominator counts
the number of calculation points in the CTV according
to scenario s.
The robust counterpart of the (LDV)model is
(RC) max V
s.t. V ≤ Csv
Cs e
∀ s ∈ S (4)
ÛdTi t ≥Dpresvi ∀ i ∈ I˜C (5)
t ≥ 0
vi ∈ {0,1} ∀ i ∈ I˜C (6)
ÛdTi t ≤ LR + (HR −LR)(1−wi) ∀ i ∈ IR∑
i∈IR
wi ≥ τR |IR |
wi ∈ {0,1} ∀ i ∈ IR
[additional constraints are in the
See Section 1 in the online supplement].
Initial tests show that (RC) yields a risk of over-
dosage, reflected by V200%(CTV) exceeding the desired
maximum level as shown in Table 1. Therefore, we
added the following constraints to (RC) to limit V200%
for each scenario:
ÛdTi t ≤ 2Dpres +Mui ∀ i ∈ I˜C
Csu
Cs e
≤ 0.2 ∀ s ∈ S (7)
ui ∈ {0, 1} ∀ i ∈ I˜C ,
where ui is a binary variable that is 0 only if calculation
point i receives at most twice the prescription dose and
1 otherwise, and M is an arbitrary large number. We
have for scenario s that V s200%(CTV)  Csu/Cs e, which
is restricted to be at most 0.2 according to the protocol
by Hoskin et al. (2007); see Table 1.
The number of variables and constraints in (LDV)
and (RC) are shown in Table 2, where we only con-
sider the constraints and variables related to the target
volume and skip the constraints and variables corre-
sponding to OAR, sparing maximum dwell times and
catheter choice, as these are identical for both mod-
els. This table clearly shows the major advantage of
our approach: The number of binary variables does
not increase with the number of scenarios |S |, but only
with the number of calculation points in the uncer-
tainty region | I˜C |. The number of constraints increases
linearly with |S |.
2.4. Accounting for Uncertainties in
Rectum Delineation
To our knowledge, delineation uncertainties in the
OARs are unaccounted for in clinical practice. The de-
lineation of the urethra is rather accurate, as a Foley
catheter is usually inserted that iswell visible on images
acquired before treatment planning. There is, however,
variability in the rectal wall thickness. Indeed, the pos-
terior rectal wall is invisible and not delineated when
using transrectal ultrasound imaging. However, this
volume receives little ornodose and is irrelevant.Delin-
eation uncertainties in the cranial and caudal, as well as
the lateral direction of the rectum, are also irrelevant, as
these areas receive hardly any dose. Therefore, we only
consider variabilities in delineating the anterior rectal
wall.
Variabilities in delineation of the rectum can be ac-
counted for using a margin or following a robust op-
timization approach. We consider the scenario-based
margin.
Table 2. Problem Sizes for (LDV) and (RC)
(LDV) (RC)
No. of binary variables |IP | 2| I˜C |
No. of continuous variables | J | | J |
No. of constraints |IP | 2|S | + 2| I˜C |
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For the robust optimization approach, we derive the
robust counterpart of constraints (2) and (3). Following
the same approach as for the PTV, we consider a set of
scenarios for the delineation of the rectum. The rows
of the matrix R correspond to the calculation points,
and the columns correspond to the scenarios. An ele-
ment Ris equals 1 if calculation point i is in the rectum
according to scenario s, and 0 otherwise. We obtain the
following robust counterpart of constraints (2) and (3):




where I˜R is the set containing all calculation points in
the rectum according to at least one scenario.
It could be that the sets I˜C and I˜R overlap in space.
However, as a different set of calculation points is gen-
erated for each structure, it is not possible that one
calculation point belongs to two structures for some
scenarios, and hence that two different restrictions are
imposed for a single calculation point. This allows us
to separately consider the worst case for the objective
function and each constraint.
2.5. Reduction of Solution Times
Even though the number of binary variables increases
only with the size of the uncertainty region, the solu-
tion time becomes more than several days, which is too
long for the model to be used in practice, or may not be
solved at all due tomemory issues.We combine several
heuristics to speed up the optimization. The algorithm
is summarized in Figure 3.
First, we relax the requirement vi ∈ {0, 1} to vi ∈
[0, 1] for the CTV. Besides strongly reducing the num-
ber of binary variables and thus the calculation times,
this relaxation has an appealing interpretation. For the
binary variables and the continuous relaxationwe have
that vi  1 when calculation point i receives at least
the prescribed dose. When i receives a dose below the
prescription dose, the binary vi equals 0, whereas the
continuous variable vi equals the delivered dose as a
fraction of the prescribed dose. Thus, the dose to calcu-
lation point i is still pushed upward in the relaxation.
Second, optimization speed is improved by exploit-
ing the fact that calculation points close to the catheters
are likely to receive a high dose, while calculation
points at a farther distance are likely to receive a low
dose (see Nath et al. 1995). So, it may not be neces-
sary to optimize for all calculation points in I˜C . We
initially assume that the calculation points near the
catheters, denoted by the set I˜nC , receive at least the pre-
scribed dose (i.e., vi  1 ∀ i ∈ I˜nC), and that calculation
points far from the catheters, denoted by I˜ fC , do not














Update S100% and S200%
Was S100% or S200% updated?
No
Yes






Note. Details of the procedures “Input and initialize,” “Update I˜nC
and I˜ fC ,” and “Update S100% and S200%” are in Section 2 of the online
supplement.
receive more than 2Dpres (i.e., ui  1 ∀ i ∈ I˜ fC). An exam-
ple of such sets is illustrated in Figure 4. One could
define these sets based on, e.g., the distance to the near-
est dwell position. We define these sets based on the
outcome of the nominal optimization model: All calcu-
lation points that receive a dose above Dpres or below
2Dpres when applying the nominal treatment plan opti-
mized with (LDV) are included in I˜nC and I˜ fC , respec-
tively. Note that no assumptions on the dose levels
received are made for the calculation points outside I˜nC
and I˜ fC . (RC) is optimized where constraints (4) and (7)
only apply to calculation points in I˜C\I˜nC and I˜C\I˜ fC ,
respectively. We check each of the calculation points in
Figure 4. Example of Sets of Calculation Points That Are
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I˜nC and I˜
f
C to see if they receive a sufficiently high and
low dose. If not, we exclude a predetermined number
of the coldest and hottest calculation points from the
sets I˜nC and I˜
f
C , respectively, and re-optimize using the
previous optimal treatment plan as a starting solution.
We excluded η100% | I˜C | and η200% | I˜C | calculation points
per iteration from the sets I˜nC and I˜
f
C in our experiments,
where η100% , η200% ∈ [0, 1]. This process is continued
until the number of calculation points for which we
made an incorrect assumption is sufficiently low (see
Figure 3, and Section 2 of the online supplement).
Third, we implement the adversarial approach
(Bienstock and Özbay 2008), which implies that only a
subset of the scenarios is included in the optimization.
We define two sets, S100% ⊂ S and S200% ⊂ S. The first,
S100%, contains those scenarios that determine theworst
case V100% in the objective, while the second, S200%, con-
tains those scenarios for which we require V200% ≤ 0.2.
The robust model is thus solved with S replaced by
S100% in the V100% objective and S replaced by S200%
for the constraint on V200% of the CTV. This means that
the resulting optimal solution is robust with respect to
the scenarios in S100%, and V200% ≤ 0.2 for the scenarios
in S200%. Using the optimal treatment plan, the scenario
with the lowest V100%(CTV) is added to S100%, unless it
is already in the set. Furthermore, if the highest V200%
over all scenarios is larger than 0.2, the corresponding
scenario is added to S200%. The new model instance is
solved using the previous optimal solution as a starting
point. The scenario sets are updated until no scenar-
ios are added to either of the sets. Initially, S100% only
contains the nominal scenario and S200% is empty (see
Figure 3, and Section 2 of the online supplement).
The final iterations in the optimization are often
spent on improving the optimality bound while the
objective value largely plateaus. Furthermore, improv-
ing the objective a little may, in practice, have little
effect on the dose to the tumor or OARs. It is thus
unnecessary to solve the model to optimality. This par-
ticularly holds for optimization of the catheter config-
uration: The minor improvements in the final itera-
tions are likely to result from a change in dwell times,
not from a change in catheter configuration. We there-
fore optimize the robust model up to a pre-determined
optimality gap g1, fix the catheter configuration, and
Table 3. Tissue Structure Volumes (cc)
Structure Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Nominal CTV 31.7 55.2 47.6 31.0 40.1 32.7
Isotropic margin PTV 39.6 62.8 63.2 37.0 43.8 37.4
Scenario-based PTV 54.5 97.3 70.8 57.4 57.6 59.9
Nominal rectum 6.8 7.5 9.4 19.5 20.7 16.3
Scenario-based rectum 8.5 8.8 12.4 20.3 20.2 16.5
Urethra 2.1 2.6 2.3 1.3 3.0 1.3
continue optimizing the beam-on times up to a second,
smaller optimality gap g2 (see Figure 3).
3. Computational Experiments
3.1. Patient and Source Data
We use data from six prostate cancer patients to test
our robust optimization method. The data is included
as a supplement to this paper. Delineations of the
CTV, rectum, and urethra were obtained from the
treatment planning system, see Table 3 for the struc-
ture volumes. Data from patients 1, 2, and 3 were
obtained from the planning system HDRplus (Eckert
and Ziegler BEBIG GmbH, Berlin, Germany) and have
previously been used in Gorissen et al. (2013) and
Balvert et al. (2015). The delineations were originally
made on images obtained with transrectal ultrasound.
For these three patients, catheter and dwell locations
could be obtained from the treatment planning sys-
tem as well. Data from patients 4, 5, and 6 were
obtained from Oncentra Brachy (Nucletron, Veenen-
daal, Netherlands), and were previously used in Deist
and Gorissen (2016). The images of these patients
were made using computed tomography. No data on
catheter locations and dwell positions were available
from the planning system andwere therefore added by
virtually placing a template in front of the perineum
using MATLAB Release 2012b (MathWorks, Inc., Nat-
ick, Massachusetts).
Calculation points for all patients were hexagonally
distributed over the structures using MATLAB Release
2012b (MathWorks, Inc., Natick, MA), see Table 4 for
details. We used the same number of dose calculation
points for optimization as did the treatment planning
system; we used a larger set for the dosimetric evalua-
tion of the treatment plan to obtainmore accurate DVH
measures. As the first three patients were imaged with
transrectal ultrasound, only the anterior rectum wall
was delineated, while for patients 4, 5, and 6 the com-
plete rectum volume was delineated on the computed
tomography scans. As the density of the calculation
points was the same for all patients, the set of rectum
calculation points is larger for patients 4, 5, and 6 than
for the first three patients.
Dose rates were calculated according to the
TG-43 formalism (Nath et al. 1995), for which
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Table 4. Number of Dose Calculation Points
Optimization
Structure (set of cps) Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6
Nominal CTV (IC) 1,750 1,759 1,743 1,757 1,749 1,743
Isotropic margin PTV (IP) 1,777 1,754 1,757 1,790 1,772 1,795
Scenario-based PTV (I˜C) 2,959 2,766 2,729 3,322 3,228 3,109
Nominal rectum (IR) 249 253 251 257 259 256
Scenario-based rectum (I˜R) 312 298 333 268 265 259
Urethra (IU ) 465 489 488 479 482 465
Evaluation
Nominal CTV (IC) 8,108 8,112 8,246 8,676 8,166 8,058
Isotropic margin PTV (IP) 7,955 7,892 8,423 8,214 8,273 8,133
Scenario-based PTV (I˜C) 20,790 23,393 26,654 15,951 14,441 15,365
Nominal rectum (IR) 2,586 2,533 2,542 6,252 6,283 6,124
Scenario-based rectum (I˜R) 3,205 3,359 3,450 6,552 6,441 6,625
Urethra (IU ) 2,114 2,163 2,314 1,992 2,090 1,956
Note. Pt Patient, cpsCalculation points.
192Ir source-specific parameters were obtained from
Granero et al. (2006). The number of possible catheter
positions and corresponding dwell positions are
shown in Table 5.
3.2. Experimental Set-up
We defined the uncertainty region for the CTV with
scenarios obtained from the original contours by
stretching or shrinking the delineated target volume
in the left, right, anterior, posterior, superior, and infe-
rior direction. The centroid-to-surface distances in each
directionwere varied independently of each other. Dis-
tances were assumed to vary at most two standard
deviations from the mean (delineated) distance. Stan-
dard deviations were obtained from Smith et al. (2007).
For patients 1, 2, and 3, with whom transrectal ultra-
sound imagingwas used, the standard deviations were
2.2 mm for the superior and inferior directions, and
1.15 mm for the remaining directions. Patients 4, 5,
and 6 were imaged using computed tomography; their
standard deviations were 1.15 mm in the cranial and
caudal directions, 1.7 mm in the lateral directions, and
1.6 mm and 2 mm in the anterior and posterior direc-
tions, respectively. For patient 2, the original, small-
est, and largest possible CTV shapes are depicted in
Figure 5.
An uncertainty region for the rectum delineation
was constructed through scenario generation as well.
Table 5. Number of Catheters and Dwell Positions
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6
Catheters 40 49 43 51 51 71
Dwell positions, original set 369 711 716 414 454 481
Dwell positions, extended set 432 813 836 657 582 653
Note. Pt Patient, cpsCalculation points.
However, only variations in the anterior direction are
of interest for the rectum, as this is where the highest
dose is deposited. As a result, only three scenarios are
included in the optimization: the smallest, the nomi-
nal, and the largest possible delineation. The smallest
(largest) scenario was generated by shrinking (stretch-
ing) the rectum volume in the anterior direction by two
standard deviations. We assume a standard deviation
of 0.5 mm.
This method of scenario generation is straightfor-
ward as it neglects the fact that delineations of an ob-
server may deviate from those delineated by others in
a consistent manner; for example, one observer may
always draw larger shapes than his/her colleague. The
assumption of independent deviations in each direc-
tion may thus be invalid. However, to our knowledge,
there is no data available on this dependency. Our
method can be easily adapted if such data becomes
available.
We considered only the minimum, nominal, and
maximum distance for each direction to limit the num-
ber of scenarios taken into account in the optimization
process, which gives 36  729 possible shapes. Note
that the assumption of independent deviations for each
direction may result in unrealistically large or small
shapes, e.g., when we fully stretch the shape in each
direction, clinically, the volume becomes unrealistically
large. Therefore, all scenarios with a clinically unre-
alistic CTV volume (smaller than 20 cc or larger than
65 cc) were excluded before optimization. This results
in 596, 534, 602, 666, 729, and 729 scenarios for the six
respective patients. To evaluate the plan quality, over
5,000 CTV scenarios were generated for each patient
by randomly drawing centroid-to-surface distances for
each direction. Again, extremely small and large sce-
narios were excluded. Recall that for the rectum only
the uncertainty in the anterior rectal wall is relevant,
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Figure 5. Vectorized Figure of Minimal (Dark Gray),
Delineated (Medium Gray), and Maximum (Light Gray)
CTV Shape
which allows us to generate scenarios by stretching or
shrinking the rectum in the anterior direction only. We
generated 101 scenarios for which the factors by which
the rectum was shrunk or stretched were sampled at
equal distances on the interval from the minimum to
the maximum possible deviation.
Models were compared based on DVH evaluation
criteria for all scenarios as well as solution times. The
models were solved using the Gurobi 5.5 optimizer
(Gurobi Optimization, Inc., Houston, Texas) interfaced
with MATLAB Release 2012b on a computer with an
Intel i7-2670 QM processor.
The dwell positions that correspond to each catheter
location are predefined by the planning software. Only
the dwell positions in the PTV were activated and
included in the optimization process. As the union
of the CTV scenarios is larger than the original tar-
get volume, some dwell positions were excluded from
the optimization process although they may be inside
the target volume. It may thus be necessary to include
additional dwell positions for each catheter. This is
illustrated in Figure 6, where the PTV is delineated
in white. The red dwell positions are included in the
original data set, which can be extended by including
the white dwell positions. All models are solved once
using the original and once using the extended set of
dwell positions.
A total of 10 treatment plans are optimized for
each patient. The different optimization approaches are
denoted by a three-letter code. The first letter denotes
the approach taken to account for uncertainties in the
delineation of the CTV, where I denotes the use of an
isotropic CTV-to-PTV margin, S denotes the scenario-
based margin, and the robust optimization approach is
denoted by R. The second letter indicates the approach
Figure 6. Sagittal Transrectal Ultrasound Scan with the PTV
Delineated in Gray
Note. The black dwell positions are included in the original data
set; the white ones are added to obtain the extended set of dwell
positions.
used to account for delineation uncertainties of the
rectum, where N denotes the use of the nominal rec-
tum delineation, and S and R are as before. Finally, the
third letter indicates whether the original (O) or the
extended (E) set of dwell positions is used. For exam-
ple, INO denotes the optimization approach followed
in the clinic, where an isotropic CTV-to-PTV margin
is used, the nominal delineation is included for the
rectum (so rectum delineation uncertainty is ignored),
and the original set of dwell positions is used. An
overview of the various settings used for the five opti-
mization approaches is shown in Table 6.
The optimality gap g2 is chosen as the smallest value
for which the algorithm terminates within 15 minutes
(a clinically acceptable optimization time) when opti-
mizing RNO. This value differs per patient and can
only be found through a trial-and-error search. The
optimality gaps are shown in Table 7. Note that for
patient 2 the optimality gap had to be adapted for the
margin approach, as the optimizer ran out of memory
for smaller values for g2. The parameter g1 is twice g2.
Parameters η100% and η200%, the fractions of calculation
points added to the sets I˜nC and I˜
f
C in each iteration,
respectively, were 0.10.
3.3. Numerical Results
We first look at the effects of using continuous instead
of binary variables v by comparing the results obtained
with (LDV) to results obtained with its relaxation (Sec-
tion 3.3.1). In Section 3.3.2, we compare the proposed
methods to account for delineation uncertainties.
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Table 6. Overview of the Settings Used for Each Optimization Approach
Method to account for uncertainties:
in CTV in rectum Dwell positions
INO Isotropic margin None Original set
RNO Worst case robust None Original set
RRO Worst case robust Worst case robust Original set
SNO Scenario-based margin None Original set
SSO Scenario-based margin Scenario-based margin Original set
INE Isotropic margin None Extended set
RNE Worst case robust None Extended set
RRE Worst case robust Worst case robust Extended set
SNE Scenario-based margin None Extended set
SSE Scenario-based margin Scenario-based margin Extended set
Finally, we look at the effects of changing the algorithm
parameters in Section 3.3.3.
3.3.1. Binary vs. Continuous Variables v. Wefirst con-
sider the (LDV) model optimized with and evaluated
in the nominal scenario only (INO). The relaxation of
the (LDV)model for the nominal case results in a large
reduction in solution times without a significant com-
promise in plan quality (Table 8). Note that for patient 1
the dose requirement D0.1cc is slightly violated, though
the violation is small and clinically irrelevant. The solu-
tion times of the robustmodel without the relaxation of
vi and the proposed algorithm from Figure 3 are unac-
ceptable: After 5 hours, the optimality gaps remained
at approximately 5%, 15%, and 10% for patients 1, 2,
and 3, respectively. This makes the model with binary
variables unusable and the relaxation necessary.
3.3.2. Comparison of the Treatment Plan Optimization
Approaches. Treatment plans were generated for each
patient using the 10 models from Table 6 where the
solution times of the margin and the robust models
were reduced using the algorithm in Figure 3. The
nominal model was solved to optimality without using
the algorithm
Treatment plan quality in terms of DVH parameters.
We are interested in the distribution of the CTV and
rectumDVH parameters over the scenarios. In Figure 7
we show the cumulative distribution of D90%(CTV),
V100%(CTV), V150%(CTV), V200%(CTV), D10%(Rectum),
and D2cc(Rectum) for patient 1. Similar figures for
patients 2–6 are provided in Section 3.1 of the online
supplement (Figures 1–5). For example, in Figure 7(c)
Table 7. Optimality Gaps (g2 in the Algorithm) Used for the Individual Patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Gap (%) robust models 0.400 0.150 0.025 0.400 0.100 0.200
Gap (%) margin models 0.400 1.000 0.025 0.400 0.100 0.200
Note. The robust approach comprises models RNO, RRO, RNE, and RRE, and the scenario-based margin approach comprises models SNO,
SSO, SNE, and SSE.
we see that for the plan generated for patient 1 using
the INO approach (solid black curve), approximately
20% of the scenarios had a V150%(CTV) of 0.45 or lower.
The gray area denotes values below the desired mini-
mum value for D90%(PTV) and V100%(PTV), and above
the desired maximum value for the remaining DVH
parameters. For completeness, Table 2 in Section 3.2
of the online supplement shows the DVH parameters
for the urethra. This table shows that the constraint
D10%(Urethra) is always satisfied.
Recall that our aim is to achieve high D90%(CTV) and
V100%(CTV), where we aim to achieve minimum levels
of 1.00 and 0.90, respectively. A curve is thus supe-
rior to another curve if it lies further to the right; our
preference would be a curve that lies completely to the
right of the minimum level. Similarly, for V150%(CTV),
V200%(CTV), D10%(Rectum), and D2cc(Rectum) curves
that lie further to the left are superior, as we prefer
these parameters to be small.
We first consider themodels forwhich rectumuncer-
tainties are unaccounted. When comparing RNO and
RNE to INO and INE, respectively, we observe a shift
of the complete curve of V100%(CTV) toward the higher
values in almost all cases. Exceptions are RNO for
patient 2, which performs better than INO for theworst
15% but worse for the remaining 85% of the simulated
delineations; RNE for patient 6, which performs better
than INE for the worst 10% but worse for the remain-
ing 90% of the simulations; and RNE for patient 1,
where the curve lies slightly more toward the lower
values than the curve corresponding to INE. Except for
patient 2, SNO and SNE always yield betterV100%(CTV)
than INO and INE, respectively. The scenario-based
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Table 8. Comparison of Treatment Plans Generated with (LDV) (Without Relaxation) and
Plans Generated with a Relaxation of (LDV)
Patient 1 Patient 2 Patient 3
DVH parameter Unit (LDV) Relaxation (LDV) Relaxation (LDV) Relaxation
D90%(PTV)≥ 1.00 % 1.13 1.15 1.07 1.07 1.05 1.05
V100%(PTV)≥ 0.90 % 0.99 1.00 0.97 0.97 0.97 0.97
V150%(PTV)≤ 0.55 % 0.50 0.51 0.25 0.29 0.26 0.27
V200%(PTV)≤ 0.20 % 0.20 0.26 0.09 0.13 0.10 0.11
D10%(Rectum)≤ 7.2 Gy 6.8 7.3 7.2 7.2 6.9 7.0
D2cc%(Rectum)≤ 6.7 Gy 5.8 6.3 6.2 6.2 6.0 6.1
D10%(Urethra)≤ 10 Gy 9.8 10.0 9.8 9.7 9.5 9.7
D0.1cc%(Urethra)≤ 10 Gy 10.0 10.2 10.0 9.9 9.7 9.8
Solution time s 14 8 385 26 25 14
Patient 4 Patient 5 Patient 6
DVH parameter Unit (LDV) Relaxation (LDV) Relaxation (LDV) Relaxation
D90%(PTV)≥ 1.00 % 1.13 1.13 1.12 1.14 1.14 1.16
V100%(PTV)≥ 0.90 % 0.98 0.98 0.98 0.98 0.99 0.99
V150%(PTV)≤ 0.55 % 0.47 0.49 0.42 0.45 0.50 0.50
V200%(PTV)≤ 0.20 % 0.26 0.29 0.19 0.22 0.26 0.24
D10%(Rectum)≤ 7.2 Gy 5.5 5.6 5.2 5.2 5.6 5.8
D2cc%(Rectum)≤ 6.7 Gy 5.5 5.6 5.2 5.2 5.3 5.5
D10%(Urethra)≤ 10 Gy 9.8 10.0 9.8 9.8 9.7 9.9
D0.1cc%(Urethra)≤ 10 Gy 9.7 9.9 9.8 9.8 6.5 6.4
Solution time s 2,302 498 116 10 35 9
margin and the robust optimization approach perform
equally well in terms of target coverage.
Including rectum delineation inaccuracies in the
optimization process, i.e., using the RR and SS models
instead of the RN and SNmodels, respectively, yields a
lower rectumdose for patients 1, 2, and 3. For patients 2
and 3 this also implies reduced target coverage. Includ-
ing rectum delineation uncertainties does not affect
treatment plans for patients 4, 5, and 6, as the rectum
dose is already sufficiently low for these three patients:
The constraint on the rectum dose was never active.
The use of a scenario-based CTV-to-PTV margin in
the SN and SS models often yields an overdose to the
target volume in terms of V200%(CTV) compared to RN
and RR. This is clear from the shift of the correspond-
ing curves toward the right for patients 1, 4, 5, and 6.
This shift is not visible for patients 2 and 3, though
V200%(CTV) never exceeds the maximum allowed value
of 0.2 for these two patients and thus was never an
active constraint. The risk of an overdose is much lower
for the RN and RR models.
When comparing the use of an extended set of dwell
positions to using the original set for the same model
(e.g., compare INO to INE or RRO to RRE), in almost
all cases the extended set allows for a reduction in
V150%(CTV) and V200%(CTV) with little or no compro-
mise on V100%(CTV). It does, however, often yield an
increased rectum dose.
Solution times. The solution times of all methods for
all patients are reported in Table 9. The solution times
for RN, RR, SN, and SS approaches are still clinically
acceptable due to the choice of the accepted optimality
gaps. Note that the solution times of RR and SS, i.e.,
thosemodels where rectum delineations are accounted
for, are always the same.
3.3.3. Changing the Algorithm’s Input Parameters.
Several parameters that form an input to the optimiza-
tion algorithm can affect the algorithm’s performance
in terms of objective value, plan quality, and solution
time. In this section, we examine the effects of chang-
ing the accepted optimality gaps and the sizes of the
volume fractions to be removed from the sets of calcu-
lation points.
Optimality gaps g1 and g2. The algorithm optimizes
an instance at each iteration until the optimality gap
g1 is achieved. After all stopping criteria have been
satisfied (see Figure 3), the catheter positions are fixed
and the dwell times are further optimized where in
each iteration an instance is optimized up to optimality
gap g2 < g1.
To see the effects of choosing a different optimal-
ity gap, we optimized RNO for various values of g2
for patients 1 and 3. We have evaluated the opti-
mizations in terms of solution time, objective function
value, and worst case V100%(CTV) for the set of scenar-
ios included in the optimization as well as the simu-
lated scenarios used in our assessment of plan quality.
Detailed results are shown in Table 3 in Section 4 of the
online supplement. We did not consider gaps smaller
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Note. The gray area indicates scenarios where the DVH requirement from Table 1 was not met.
than 0.025%, as this is already very small. Optimiz-
ing RNO for patient 1 for g2  0.3% took more than
three hours, so the model was not optimized for gaps
smaller than 0.3%. Optimizing up to a g2 smaller than
0.4% yields clinically unacceptable solution times for
patient 1. However, setting g2  0.4% gives a much
lower worst case V100%(CTV) than with g2  0.025% for
patient 3, i.e., 87.8 versus 92.7. It is thus necessary to
individually determine a suitable g2 for each patient.
Fractions of calculation points η100% and η200%. The
model is optimized for subsets of the calculation points
at each iteration. The algorithm also checks, per itera-
tion, if the worst case V100%(CTV) and V200%(CTV) ob-
tained for the optimized instance are sufficiently close
to the real values. If this is not the case, then the sets of
calculation points are extended. Recall that the param-
eters η100% and η200% determine the fractions of I˜C that
are removed from I˜nC and I˜
f
C , respectively. To see the
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Table 9. Solution Times in Seconds
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
INO 14 385 25 2,302 116 35
RNO 571 98 183 912 220 528
RRO 65 313 256 344 493 496
SNO 880 123 213 612 844 362
SSO 63 313 260 335 481 496
INE 20 439 31 804 83 12
RNE 325 218 351 53 75 150
RRE 41 88 101 75 348 365
SNE 399 87 324 52 83 144
SSE 41 87 101 74 347 366
effect of the choices for these parameters, we have opti-
mized RNO for patient 1 for various values of η100%
and η200%. The results presented in Table 4 in Section 4
of the online supplement show that the choice of η100%
and η200% hardly influences the objective function value
and the worst case V100%(CTV), but they significantly
influence the solution times. There is, however, no clear
relation between the choice of η and the solution times.
This can be explained by the trade-off that one makes
when choosing η: A small η results in adding few cal-
culation points to the optimization problem in the next
iteration, which makes the optimization fast but could
result in the need for more iterations. By contrast, a
large η adds many calculation points to the optimiza-
tion in each iteration, hence slowing the optimization
but reducing the number of required iterations.
4. Discussion
Our results indicate that target coverage is improved
by using the scenario-based margin model instead of
the isotropic 2 mm CTV-to-PTV margin, which implies
that the 2 mm margin used in the clinic may be insuf-
ficient. This particularly holds for the anterior and
posterior directions of the CTV, where the delineation
uncertainty is larger than in other directions (Smith
et al. 2007). We conclude that an isotropic margin is
inadequate. A downside of the scenario-based margin
model is an increased V200%(CTV), which agrees with
the findings from Tanderup et al. (2010). The robust
treatment planning model results in an improvement
in target coverage similar to the scenario-based margin
approach. Additionally, in this model an overdosage,
reflected in excessively high values for V200%(CTV),
can be prevented by adding a constraint that requires
V200%(CTV) to be below a preset level for each of the sce-
narios. This constraint does not work well for the mar-
gin approach, since in that case no individual scenar-
ios are considered; thus, the constraint on V200%(CTV)
applies to an extended CTV only, which is a rather
large volume. As a result, individual scenarios were
not protected from overdosage.
The dose escalation in the CTV may be caused
by the absence of dwell positions in the margin vol-
ume. Therefore, we optimized a treatment plan with
the scenario-based margin approach using additional
dwell positions in the scenario-based margin. As this
did not improve the treatment plan quality, we con-
clude that dose escalation inherent to the margin
approach cannot be prevented by includingmore dwell
positions.
Uncertainties in the delineation of the rectum yield
risk of a rectal overdose for some patients. Our results
substantiate this outcome: For those patients, account-
ing for rectum delineation uncertainties reduces this
risk. For two out of three patients for whom this risk
was reduced, this comes at a cost of a reduced coverage
of the target volume.
The solution time and the optimality gap vary
strongly among patients. Note that solution times vary
for the nominal model as well. Furthermore, the solu-
tion time of the robust model halves for patient 1
when adding dwell positions, whereas it doubles for
patient 2. These discrepancies may be caused by how
much “luck” we had with the branch-and-bound tree
(which also holds for the nominal optimizationmodel).
The iterative nature of our approach introduces an
additional factor of “luck” in the search for an optimal
solution: For one case, the procedure chose the most
important scenario early, whereas more iterations were
needed in another case.
For patients 1, 2, and 3 images were acquired using
transrectal ultrasound imaging, whereas CT images
were acquired for patients 4, 5, and 6. This results in
a different delineation of the rectum: With transrectal
ultrasound only the anterior wall is delineated, while
the whole rectum is delineated on CT images. As a
result, the rectum volumes for patients 4, 5, and 6
are approximately twice as large as for patients 1, 2,
and 3. This implies that the constraint on rectum dose,
D10%(Rectum)≤ 7.2 Gy, is less restrictive for the CT
patients than for the ultrasound patients. This is inher-
ent when using a restriction on a structure’s relative
volume. For our study, however, it has an advantage:
The results show that including rectum delineation
uncertainty yields a reduction in target coverage when
D10%(Rectum)was above 7.2 Gy for a large subset of the
scenarios, whereas target coverage is unaffected when
D10%(Rectum)≤ 7.2Gywas satisfied for most of the sce-
narios.
Our approach may be applicable for other body
sites but would require reliable data on target volume
and OAR delineation uncertainties of the particular
organ(s) in question. Furthermore, one may apply our
method to set-up uncertainties by viewing these varia-
tions as a rigid shift of the organs and hence the delin-
eations, leaving the position of the calculation points
and hence the dose rate fixed. This would allow us
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to combine all uncertainties into one composite uncer-
tainty in the index set. A thorough investigation is
mandatory to assess the feasibility and value of this
approach. Moreover, this approach can be used not
only for HDR Brachytherapy but also for external beam
radiotherapy.
The core idea of this paper on how toaddress uncer-
tainties in index sets could also be applicable to other
Operations Research (OR) problems. A first type of
optimization model has uncertainty in the time index.
For instance, supply chain models often have uncer-
tainty in the lead time. In the food supply chain model
for the UN World Food Program (Peters et al. 2016),
for example, there is much uncertainty in the lead
time because of possible congestion in the harbors.
Optimization models with different sets of restrictions
for different types of customers, regions, parts, etc.,
are other possibilities. An example could be inven-
tory models with different categories of service levels,
depending on customers’ characteristics, and where
there is uncertainty about the required service level
category for a subset of future customers. Another
example is optimizing flood protection measures for
the coming centuries such that all safety levels are sat-
isfied (Postek et al. 2018).
5. Conclusion
The worst-case robust treatment plan optimization
model presented in this work for prostate HDR BT
is capable of accounting for target volume and rec-
tum delineation uncertainties. Uncertainties in index
sets can be accounted for using a scenario-based ap-
proach. Although the treatment plan optimization
model becomes too large to be solved within a clini-
cally acceptable amount of time, our heuristic approach
reduces the calculation times to acceptable proportions
for the nominal and the robust optimization models.
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